Korea Institute of Science and Technology

University of California

Hanmi Science Co., Ltd.

Industry-University Cooperation Foundation Hanyang University

Korea Research Institute of Chemical Technology

Korea Research Institute of Bioscience and Biotechnology

Hanmi Pharm. Co., Ltd.

Catholic University Industry Academic Cooperation Foundation

Daegu-Gyeongbuk Medical Innovation Foundation

Pharos Ibio Co., Ltd.

Tae Bo Sim

Hwan Geun Choi

Young Jin Ham

Ho Jong Yoon

Woo Young Hur

Jung Mi Hah

Hwan Mook Kim

Kyung Ho Yoo

Jung Beom Son

Chi Man Song

Han Na Cho

Chang Hyun Oh

Eun Joo Roh

Hwan Oh Kim

Yun Ju Nam

Henry Rapoport

Young Gil Ahn

Maeng Sup Kim

Seung Hyun Jung

Young Hee Jung

So Ha Lee

Seung Hye Choi

Seung Min Lee

Tae Young Kim

Dong-wook Kim

Jae Ho Kim

So Young Kim

Jae Chul Lee

Eun Young Kim

Ji Yeon Song

Sung Yun Cho

Dong Cho Han

Jae Du Ha

Nam Doo Kim

Jae Yul Choi

Yi Kyung Ko

Hyun Kyoung Kim

Byoung Mog Kwon

Seock Yong Kang

Mi Kyoung Lee

Suk Kyoon Yoon

Eun Hwa Ko

Jae Hyun Bae

Gu Kong

Ky Youb Nam

Eun Hye Ju

Dong Sik Park

Jung Hun Lee

Eun Jin Jun

Dong-sik Park

Tae Hun Song

In Jae Shin

Jeong Yeon Lee

Jeong Hyeok Yoon

Jung-Hun Lee

Seo Jung Han

Seung Yeon Lee

Yeon Ui Kwak

Seong Shick Ryu

Dong Keon Hwang

Do Hee Oh

In Jae Shun

Byeong Yun Lim

Wha Ii Choi

In Ho Yang

Nam Kyoung Kim

Jae Eun Cheong

Ji Hye Yoon

Kyu Hang Lee

Eun Ju Jeon

Joong Heui Cho

Myoung Sil Ko

Wha Il Choi

Hwan Kim

Dong-Wook Kim

The present invention relates to: a compound selected from among a novel pyridinyltriazine derivative having protein kinase inhibitory activity, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof; a method for preparing the compound; and a pharmaceutical composition which is for preventing, alleviating, or treating cancer and comprises the compound. A novel compound according to the present invention exhibits excellent inhibitory effects against FGFR, which is a major trigger of bladder cancer, endometrial cancer, etc., point mutations thereof, and various protein kinases other than FGFR involved in signal transduction, and is thus effective as an agent for preventing and treating abnormal cell growth diseases caused by such protein kinases.

Pyridinyltriazine derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, ameliorating, or treating cancer comprising same

Disclosed are a compound selected from novel pyrimido[4,5-d]pyrimidin-2-one derivative compounds having excellent anti-proliferative activity against cancer cells, pharmaceutically acceptable salts thereof, hydrates thereof and stereoisomers thereof, a method for preparing the compound, a pharmaceutical composition for preventing, alleviating or treating cancer metastasis and proliferative diseases containing the compound as an active ingredient, and an anticancer composition against cancer cells, containing the compound as an active ingredient. The compounds of this invention exhibit most excellent selective inhibitory activity against LCK and anti-proliferative activity against cancer cells, thus being useful for inhibiting cancer cells, and for preventing or treating cancer metastasis and proliferative diseases.

Pyrimido[4,5-d]pyrimidin-2-one derivatives as protein kinase inhibitors

Disclosed are a novel pyrimidine derivative compound, a pharmaceutically acceptable salt thereof, a method for preparing the compound and a pharmaceutical use of the compound as an anticancer agent or a therapeutic agent for degenerative brain diseases. Specifically, the novel pyrimidine derivative compound has excellent inhibitory activities against kinase enzymes such as ARK5/NUAK1, ACK1, FLT3, JAK1, JAK2 and JAK2 (V617F) and thus is useful for treating and preventing leukemia, ovarian cancer, breast cancer, non-small cell carcinoma, colorectal cancer, glioma, and brain protein abnormalities such as Alzheimer's disease, progressive supranuclear palsy and frontotemporal dementia, that is, degenerative diseases caused by Tau deposition.

Multi-substituted pyrimidine derivatives with excellent kinase inhibitory activities

The present invention relates to a novel pyrimidine-4-carboxylic acid derivative having an anticancer activity, and the compound thereof is useful as a drug for treating and preventing tumor diseases, 

Substituted pyrimidine-4-carboxylic acids having anticancer activity

The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.

2,3,5-substituted thiophene compound as protein kinase inhibitor

The present invention provides a therapeutic agent of acute myeloid leukemia containing a 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1H)-one compound as an active ingredient, which has proliferation inhibitory activity for a human acute myeloid leukemia cell line OCI-AML3 having a NRAS mutant gene while having low inhibitory activity for wild type NRAS and has activity of inhibiting GCK and ACK1 protein kinases at the same time.

Therapeutic agent of acute myeloid leukemia containing 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-D]pyrimidine-2(1H)-one derivatives

The present invention relates to a therapeutic agent for chronic myelogenous leukemia with reduced drug-resistance and side-effects containing a 1,6-disubstituted indole compound.

CML therapeutic agents with reduced drug-resistance and side-effect comprising 1,6-disubstituted indole compounds

The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase

The present invention provides a pharmaceutical composition, as an effective ingredient, a urea compound having a protein kinase inhibitory activity and containing a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one skeleton, and a pharmaceutically acceptable salt thereof.

Urea compounds containing 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one skeleton as protein kinase inhibitors

The present invention relates to a novel 4-((2-acrylamidophenyl)amino)thieno[3,2-d]pyrimidine-7-carboxamide compound, an anticancer agent containing the compound as an active ingredient and an intermediate compound for preparing the compound.

4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors

A heteroarylamine compound includes protein kinase inhibition activity, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for preventing and treating a disease caused by abnormal cell growth, which contains the compound as an active ingredient.

Heteroarylamine derivatives as protein kinase inhibitors

A substituted thieno pyrimidine compound of Formula 1, pharmaceutically acceptable salts and a pharmaceutical composition thereof is provided.  The compound of Formula 1 exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction. The compound of Formula 1 and its compositions are useful for the prevention and treatment of diseases caused by abnormal cell growth including cancer.

2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors

The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases

The present invention relates to a method for preparing (+)-polyoxamic acid and a novel intermediate compound synthesized during preparation thereof. The preparation method according to the present invention allows preparation of (+)-polyoxamic acid with high optical purity in high yield. In particular, the preparation method is useful for mass production because the process is simple.

Process for preparing (+)-polyoxamic acid

Disclosed are a 1,6-substituted indole compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of cancers caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel indole compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.

1,6-disubstituted indole compounds as protein kinase inhibitors

Growing community of inventors

Seoul, South Korea

Tae Bo Sim